MeSH term
Frequency | Condition_Probility | Follow-Up Studies | 7 | 0.0 |
Humans | 974 | 0.0 |
Animals | 294 | 0.0 |
Biological Markers | 11 | 0.0 |
Time Factors | 34 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Vasoactive Intestinal Peptide/*blood | 71 | 100.0 |
Autoradiography | 16 | 3.0 |
Comparative Study | 133 | 0.0 |
Lymphatic Metastasis | 3 | 0.0 |
Receptors, Neuropeptide/*metabolism | 3 | 27.0 |
Receptors, Peptide/metabolism | 2 | 6.0 |
Receptors, Vasoactive Intestinal Peptide | 61 | 95.0 |
Tissue Distribution | 29 | 1.0 |
Cattle | 12 | 0.0 |
Cells, Cultured | 45 | 0.0 |
Cyclic AMP/*biosynthesis | 4 | 14.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 6 | 3.0 |
Drug Synergism | 11 | 0.0 |
Forskolin/pharmacology | 12 | 3.0 |
Neuropeptides/*pharmacology | 29 | 51.0 |
Potassium/pharmacology | 4 | 7.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Second Messenger Systems | 3 | 3.0 |
Tumor Cells, Cultured | 50 | 0.0 |
Vasoactive Intestinal Peptide/*metabolism | 58 | 89.0 |
Asthma/immunology | 2 | 5.0 |
Electric Stimulation | 17 | 7.0 |
Guinea Pigs | 27 | 3.0 |
Muscle Relaxation/drug effects | 9 | 39.0 |
Muscle, Smooth/*drug effects | 5 | 33.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 30 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 138 | 0.0 |
Vasoactive Intestinal Peptide/*pharmacology | 86 | 86.0 |
Vasodilator Agents/*pharmacology | 4 | 8.0 |
Adult | 337 | 0.0 |
Male | 443 | 0.0 |
Penile Erection/*physiology | 2 | 28.0 |
Reference Values | 34 | 0.0 |
Research Support, Non-U.S. Gov't | 567 | 0.0 |
Amino Acid Sequence | 67 | 0.0 |
Hamsters | 16 | 0.0 |
Mice | 40 | 0.0 |
Molecular Sequence Data | 66 | 0.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Rats | 107 | 0.0 |
Receptors, Pituitary Hormone/*metabolism | 2 | 40.0 |
Receptors, Vasoactive Intestinal Peptide/drug effects/*metabolism | 2 | 100.0 |
Aged | 173 | 0.0 |
Aged, 80 and over | 46 | 0.0 |
Disease Progression | 6 | 0.0 |
Female | 380 | 0.0 |
Immunohistochemistry | 144 | 1.0 |
Middle Aged | 288 | 0.0 |
Neoplasm Staging | 10 | 0.0 |
Binding Sites | 18 | 0.0 |
CHO Cells | 9 | 0.0 |
Calcium/*metabolism | 4 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Analysis of Variance | 10 | 0.0 |
Child | 51 | 0.0 |
Fluorescent Antibody Technique, Indirect | 12 | 1.0 |
Neurogenic Inflammation/physiopathology | 2 | 66.0 |
Neuropeptides/*biosynthesis | 3 | 50.0 |
Somatostatin/biosynthesis | 2 | 40.0 |
Statistics, Nonparametric | 4 | 0.0 |
Substance P/biosynthesis | 2 | 50.0 |
Vasoactive Intestinal Peptide/metabolism | 63 | 88.0 |
Forecasting | 3 | 0.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Cell Separation | 3 | 0.0 |
Cyclic AMP/metabolism | 34 | 6.0 |
Flow Cytometry | 2 | 0.0 |
*Lymphocyte Activation | 2 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
Peptides/immunology | 2 | 1.0 |
Receptors, Vasoactive Intestinal Peptide/genetics/metabolism | 3 | 60.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Species Specificity | 24 | 0.0 |
Transfection | 16 | 0.0 |
Vasoactive Intestinal Peptide/*chemistry | 3 | 100.0 |
Neurons/*cytology/metabolism | 2 | 7.0 |
Neuropeptide Y/*metabolism | 6 | 8.0 |
Base Sequence | 32 | 0.0 |
Blotting, Northern | 7 | 0.0 |
Cloning, Molecular | 13 | 0.0 |
DNA, Complementary/genetics/isolation & purification | 2 | 1.0 |
Peptide PHI/*metabolism | 2 | 66.0 |
Receptors, Cell Surface/*metabolism | 19 | 3.0 |
Mammals | 3 | 0.0 |
Neuropeptides/metabolism | 15 | 28.0 |
Neurotransmitters/metabolism | 3 | 8.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
Calcitonin Gene-Related Peptide/*blood | 2 | 40.0 |
Neuropeptide Y/*blood | 3 | 3.0 |
Down-Regulation | 2 | 0.0 |
Neurons/metabolism | 3 | 0.0 |
Radioimmunoassay | 95 | 5.0 |
Rats, Wistar | 9 | 0.0 |
Calcitonin Gene-Related Peptide/metabolism | 17 | 45.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
*Membrane Transport Proteins | 3 | 0.0 |
NADPH Dehydrogenase/metabolism | 3 | 12.0 |
Neuropeptide Y/metabolism | 18 | 29.0 |
Nitric-Oxide Synthase/*metabolism | 5 | 6.0 |
Substance P/metabolism | 29 | 54.0 |
Swine | 30 | 2.0 |
Tyrosine 3-Monooxygenase/metabolism | 11 | 6.0 |
*Vesicular Transport Proteins | 3 | 1.0 |
Biopsy | 15 | 0.0 |
Calcitonin Gene-Related Peptide/analysis | 49 | 70.0 |
Image Processing, Computer-Assisted | 7 | 1.0 |
Neuropeptide Y/analysis | 47 | 67.0 |
Substance P/analysis | 71 | 76.0 |
Tyrosine 3-Monooxygenase/analysis | 18 | 21.0 |
Vasoactive Intestinal Peptide/analysis | 83 | 83.0 |
Adolescent | 69 | 0.0 |
English Abstract | 64 | 0.0 |
Nerve Fibers/*chemistry | 11 | 64.0 |
Vasoactive Intestinal Peptide/*analysis | 54 | 93.0 |
Autonomic Nervous System/*anatomy & histology | 2 | 40.0 |
Immunoenzyme Techniques | 38 | 1.0 |
Neuropeptides/*physiology | 17 | 41.0 |
Blotting, Western | 5 | 0.0 |
Cell Division | 3 | 0.0 |
Cell Movement | 2 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Dose-Response Relationship, Drug | 45 | 0.0 |
Neoplasm Invasiveness | 4 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Chemotaxis, Leukocyte/*drug effects | 4 | 6.0 |
In Vitro | 79 | 1.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Calcitonin/analysis | 8 | 32.0 |
Gastrointestinal Neoplasms/*chemistry | 2 | 40.0 |
Macaca mulatta | 2 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Arousal/physiology | 2 | 9.0 |
Neurotransmitters/physiology | 3 | 9.0 |
Penile Erection/physiology | 3 | 42.0 |
Insulin/secretion | 2 | 3.0 |
Kinetics | 50 | 0.0 |
Neuropeptides/*metabolism | 35 | 41.0 |
Pancreas/secretion | 2 | 28.0 |
Substrate Specificity | 3 | 0.0 |
Calcitonin Gene-Related Peptide/pharmacology | 11 | 37.0 |
Cell Line | 45 | 0.0 |
Neuropeptide Y/pharmacology | 6 | 26.0 |
Neuropeptides/*pharmacology/physiology | 2 | 50.0 |
Somatostatin/pharmacology | 9 | 18.0 |
Substance P/pharmacology | 18 | 54.0 |
Vasoactive Intestinal Peptide/pharmacology | 48 | 60.0 |
Regional Blood Flow/physiology | 4 | 8.0 |
Transplantation, Heterologous | 4 | 0.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Gene Expression | 12 | 0.0 |
Rats, Sprague-Dawley | 14 | 0.0 |
Growth Inhibitors/*pharmacology | 3 | 1.0 |
Neurotensin/*pharmacology | 2 | 33.0 |
Receptors, Vasoactive Intestinal Peptide/metabolism | 12 | 85.0 |
Recombinant Fusion Proteins/*pharmacology | 2 | 8.0 |
Vasoactive Intestinal Peptide/metabolism/*pharmacology | 12 | 85.0 |
Gestational Age | 10 | 1.0 |
Secretin/*metabolism | 4 | 80.0 |
Cyclic AMP/biosynthesis | 11 | 8.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Muscle, Smooth/*innervation | 5 | 71.0 |
Nerve Fibers/*metabolism | 10 | 62.0 |
Prostate/*innervation | 2 | 66.0 |
Thiolester Hydrolases/metabolism | 5 | 29.0 |
Ubiquitin Thiolesterase | 35 | 33.0 |
Dopamine beta-Hydroxylase/metabolism | 3 | 12.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Parasympathetic Nervous System/*metabolism | 2 | 33.0 |
Sympathetic Nervous System/*metabolism | 3 | 37.0 |
Autopsy | 5 | 2.0 |
Calcitonin Gene-Related Peptide/*analysis | 9 | 52.0 |
Stellate Ganglion/cytology/*pathology | 2 | 100.0 |
Biological Markers/analysis | 14 | 1.0 |
Child, Preschool | 37 | 0.0 |
Culture Techniques | 4 | 0.0 |
Infant | 38 | 0.0 |
Infant, Newborn | 28 | 0.0 |
Neuropeptides/*analysis | 62 | 80.0 |
Substance P/*analysis | 17 | 56.0 |
Receptors, Cholecystokinin/*analysis | 2 | 33.0 |
Receptors, Somatostatin/*analysis | 2 | 25.0 |
Receptors, Vasoactive Intestinal Peptide/*analysis | 6 | 100.0 |
Acetylcholinesterase/analysis | 4 | 11.0 |
Pilocarpine/pharmacology | 2 | 22.0 |
Growth Hormone/*secretion | 2 | 1.0 |
Prolactin/secretion | 3 | 2.0 |
Choline O-Acetyltransferase/analysis | 3 | 6.0 |
Neurons/*chemistry/enzymology | 2 | 50.0 |
Nitric-Oxide Synthase/analysis | 4 | 26.0 |
Phosphopyruvate Hydratase/analysis | 8 | 10.0 |
Calcitonin Gene-Related Peptide/*metabolism | 2 | 15.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Ligands | 7 | 0.0 |
Fetus | 5 | 0.0 |
*Infant, Premature | 2 | 3.0 |
Somatostatin/*analysis | 2 | 11.0 |
HT29 Cells | 3 | 1.0 |
Pancreatic Neoplasms/*blood | 2 | 22.0 |
Indium Radioisotopes/diagnostic use | 2 | 11.0 |
Kidney/metabolism | 2 | 0.0 |
Receptors, Vasoactive Intestinal Peptide/*metabolism | 6 | 75.0 |
Vasoactive Intestinal Peptide/*diagnostic use/metabolism | 2 | 100.0 |
Ganglia, Autonomic/pathology | 2 | 100.0 |
Neuropeptides/*blood | 5 | 27.0 |
Models, Biological | 5 | 0.0 |
Biological Markers/blood | 2 | 0.0 |
Case-Control Studies | 11 | 0.0 |
Neuropeptide Y/blood | 3 | 13.0 |
Skin/pathology | 2 | 0.0 |
Vasoactive Intestinal Peptide/blood | 34 | 82.0 |
Gastrointestinal Motility/physiology | 2 | 28.0 |
Nervous System Physiology | 2 | 9.0 |
Immune System/*physiology | 2 | 3.0 |
*Neuroimmunomodulation | 2 | 18.0 |
Central Nervous System/immunology | 2 | 14.0 |
Autonomic Nervous System/drug effects/*physiology | 2 | 50.0 |
DNA Primers | 4 | 0.0 |
Transforming Growth Factor beta/*physiology | 2 | 1.0 |
Vasoactive Intestinal Peptide/*genetics | 14 | 73.0 |
Prostatic Neoplasms/*pathology | 3 | 2.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Neutrophils/drug effects/*physiology | 3 | 4.0 |
Lung/*metabolism | 3 | 3.0 |
Vasoconstriction/physiology | 2 | 15.0 |
Vasodilation/physiology | 3 | 10.0 |
Binding, Competitive | 24 | 1.0 |
Chromatography, High Pressure Liquid | 23 | 1.0 |
Insulin/pharmacology | 2 | 0.0 |
Peptides/*metabolism | 7 | 3.0 |
Protein Binding | 8 | 0.0 |
Receptors, Neuropeptide Y/metabolism | 2 | 15.0 |
Cisplatin/administration & dosage | 5 | 2.0 |
Disease-Free Survival | 2 | 0.0 |
Etoposide/administration & dosage | 2 | 1.0 |
Ifosfamide/administration & dosage | 4 | 17.0 |
Prognosis | 6 | 0.0 |
Adenylate Cyclase/metabolism | 29 | 21.0 |
Enzyme Activation | 13 | 0.0 |
Microscopy, Fluorescence | 6 | 0.0 |
Models, Molecular | 6 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Mutation | 3 | 0.0 |
Phenotype | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Signal Transduction | 9 | 0.0 |
Structure-Activity Relationship | 18 | 0.0 |
Cerebral Cortex/*metabolism | 4 | 7.0 |
Chickens | 7 | 0.0 |
Neuropeptides/pharmacology | 12 | 40.0 |
Organ Culture Techniques | 2 | 0.0 |
Peptide Fragments/pharmacology | 9 | 4.0 |
Tritium/diagnostic use | 2 | 1.0 |
Vasoactive Intestinal Peptide/chemistry/*pharmacology | 2 | 100.0 |
Receptors, Vasoactive Intestinal Peptide/physiology | 4 | 57.0 |
Iodine Radioisotopes/diagnostic use | 8 | 2.0 |
Cell Survival/drug effects | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 8 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Fluorescent Antibody Technique | 36 | 1.0 |
Neurons/*chemistry | 5 | 15.0 |
Neuropeptide Y/immunology | 2 | 100.0 |
Substance P/immunology | 4 | 80.0 |
Vasoactive Intestinal Peptide/immunology | 2 | 100.0 |
Dermatitis, Atopic/*metabolism | 3 | 42.0 |
Substance P/*pharmacology | 17 | 51.0 |
DNA, Complementary | 3 | 0.0 |
Vasoactive Intestinal Peptide/metabolism/pharmacology | 6 | 85.0 |
Epinephrine/secretion | 2 | 66.0 |
Neurotransmitters/*pharmacology | 6 | 42.0 |
Norepinephrine/secretion | 2 | 33.0 |
Receptors, Pituitary Hormone/antagonists & inhibitors | 2 | 66.0 |
Receptors, Vasoactive Intestinal Peptide/antagonists & inhibitors | 2 | 66.0 |
Stimulation, Chemical | 12 | 2.0 |
Chronic Disease | 14 | 0.0 |
Nerve Fibers/*pathology | 2 | 28.0 |
Nerve Tissue Proteins/analysis | 10 | 13.0 |
Thiolester Hydrolases/analysis | 18 | 51.0 |
Cytoplasm/chemistry | 3 | 1.0 |
Exocytosis | 2 | 2.0 |
Microscopy, Electron | 25 | 1.0 |
Vasoactive Intestinal Peptide/*physiology | 16 | 80.0 |
DNA Probes | 3 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Macromolecular Substances | 3 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Cell Division/*drug effects | 3 | 1.0 |
Glucagon/pharmacology | 6 | 20.0 |
Umbilical Veins | 2 | 0.0 |
Gene Expression/drug effects | 2 | 0.0 |
Inositol Phosphates/metabolism | 2 | 1.0 |
Antibody Formation | 3 | 0.0 |
Tretinoin/pharmacology | 3 | 0.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Protein Conformation | 3 | 0.0 |
Calcitonin Gene-Related Peptide/blood | 3 | 37.0 |
Veins | 2 | 3.0 |
Actins/metabolism | 2 | 0.0 |
Macaca fascicularis | 3 | 1.0 |
Nerve Fibers/metabolism | 12 | 57.0 |
Nerve Tissue Proteins/metabolism | 4 | 1.0 |
Eosinophils/immunology | 2 | 3.0 |
Immunohistochemistry/methods | 8 | 1.0 |
Mast Cells/immunology | 3 | 11.0 |
Cell Membrane/metabolism | 10 | 0.0 |
Light | 2 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cyclic GMP/metabolism | 3 | 3.0 |
Enzyme Inhibitors/pharmacology | 8 | 0.0 |
Vasoactive Intestinal Peptide/analogs & | 4 | 100.0 |
Inflammation | 2 | 0.0 |
Hypothalamo-Hypophyseal System/*physiology | 2 | 8.0 |
Pituitary-Adrenal System/*physiology | 2 | 14.0 |
Serotonin/*biosynthesis | 2 | 50.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Combined Modality Therapy | 8 | 0.0 |
Survival Analysis | 3 | 0.0 |
Vinblastine/administration & dosage | 2 | 4.0 |
Muscle Contraction/physiology | 4 | 8.0 |
Muscle Relaxation/physiology | 2 | 25.0 |
Neurons/*physiology | 5 | 3.0 |
Nitric Oxide/*physiology | 2 | 2.0 |
Nitric-Oxide Synthase/metabolism | 9 | 7.0 |
Physical Stimulation | 3 | 6.0 |
Cell Differentiation | 7 | 0.0 |
Cholecystokinin/analysis | 6 | 60.0 |
Enkephalin, Methionine/analysis | 6 | 60.0 |
Serotonin/analysis | 7 | 28.0 |
Somatostatin/analysis | 25 | 43.0 |
Vasoactive Intestinal Peptide/antagonists & | 2 | 100.0 |
Chromogranins/analysis | 7 | 13.0 |
Corticotropin/analysis | 4 | 17.0 |
Synaptophysin/analysis | 4 | 11.0 |
DNA/biosynthesis | 4 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Peptide Fragments/*pharmacology | 5 | 2.0 |
Secretin/pharmacology | 8 | 36.0 |
Enzyme-Linked Immunosorbent Assay | 10 | 0.0 |
Interleukin-6/*biosynthesis | 3 | 2.0 |
Brain/*metabolism | 4 | 0.0 |
Gene Library | 3 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
RNA, Messenger/genetics/*metabolism | 2 | 1.0 |
Sequence Alignment | 5 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Xenopus laevis | 2 | 0.0 |
Cerebrovascular Circulation/*physiology | 2 | 8.0 |
Vasodilation/drug effects | 4 | 7.0 |
Aging | 3 | 0.0 |
Catecholamines/*metabolism | 2 | 3.0 |
Vas Deferens/*innervation | 2 | 100.0 |
Iodine Radioisotopes | 8 | 2.0 |
Radioligand Assay | 7 | 1.0 |
Receptors, Vasoactive Intestinal Peptide/analysis | 2 | 100.0 |
Cell Division/drug effects | 19 | 0.0 |
Cyclic AMP/physiology | 6 | 5.0 |
Gastrin-Releasing Peptide/pharmacology | 2 | 33.0 |
Quinoxalines/pharmacology | 2 | 12.0 |
Thymidine/metabolism | 3 | 0.0 |
Nasal Mucosa/*innervation/pathology | 2 | 100.0 |
Nerve Fibers/immunology | 2 | 100.0 |
*Cerebrovascular Circulation | 5 | 14.0 |
Substance P/*blood | 6 | 50.0 |
Receptor, Cholecystokinin B | 2 | 5.0 |
Biological Transport | 3 | 0.0 |
Phosphorylation | 4 | 0.0 |
Colon/*innervation | 7 | 53.0 |
Ileum/*innervation | 2 | 100.0 |
Muscle, Smooth/innervation | 10 | 90.0 |
Nerve Fibers/ultrastructure | 5 | 33.0 |
Neuropeptides/analysis | 9 | 47.0 |
Phosphopyruvate Hydratase/*analysis | 4 | 20.0 |
Cyclic AMP/*metabolism | 8 | 3.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Receptors, Somatostatin/analysis | 2 | 28.0 |
Peritoneal Cavity/cytology | 2 | 4.0 |
Vasoactive Intestinal Peptide/physiology | 13 | 81.0 |
Endoscopy, Gastrointestinal | 2 | 10.0 |
Gastrointestinal Motility | 3 | 20.0 |
Diabetes Complications | 3 | 2.0 |
Pregnancy | 22 | 0.0 |
Adrenergic Fibers/*chemistry | 2 | 66.0 |
Vasoactive Intestinal Peptide/*analysis/immunology | 4 | 100.0 |
Blood Vessels/innervation | 5 | 62.0 |
Neuropeptides/*isolation & purification | 2 | 66.0 |
Antibodies | 6 | 1.0 |
Nerve Fibers/chemistry/enzymology | 2 | 100.0 |
Syndrome | 21 | 1.0 |
Vasoactive Intestinal Peptide/*biosynthesis | 5 | 83.0 |
Vasoactive Intestinal Peptide/blood/*cerebrospinal fluid | 2 | 100.0 |
Nerve Fibers/chemistry | 7 | 43.0 |
Amyloid/metabolism | 2 | 4.0 |
Colon/*innervation/pathology | 2 | 50.0 |
Octreotide/administration & dosage | 2 | 33.0 |
Pancreatic Neoplasms/*diagnosis/therapy | 2 | 66.0 |
Prednisolone/administration & dosage | 2 | 2.0 |
Double-Blind Method | 3 | 0.0 |
Injections | 4 | 3.0 |
Penile Erection/drug effects | 2 | 25.0 |
Chlorides/*metabolism | 3 | 4.0 |
Estrenes/pharmacology | 2 | 5.0 |
Microscopy, Electron, Scanning Transmission | 2 | 40.0 |
Neuropeptides/antagonists & inhibitors/*pharmacology | 2 | 66.0 |
Potassium/metabolism | 2 | 1.0 |
Pyrrolidinones/pharmacology | 2 | 3.0 |
Vasoactive Intestinal Peptide/antagonists & inhibitors/*pharmacology | 3 | 100.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Brain Chemistry/physiology | 3 | 11.0 |
Organ Specificity | 8 | 0.0 |
Esophagus/*innervation | 2 | 50.0 |
Mucous Membrane/innervation | 3 | 75.0 |
Proteins/analysis | 2 | 1.0 |
Animals, Newborn | 5 | 0.0 |
Injections, Intraventricular | 2 | 1.0 |
Neuroprotective Agents/*pharmacology | 2 | 2.0 |
Mice, Inbred Strains | 3 | 0.0 |
Vasoactive Intestinal Peptide/*antagonists & inhibitors/*physiology | 2 | 100.0 |
Evaluation Studies | 2 | 0.0 |
Neuroglia/pathology | 2 | 9.0 |
Neurons/pathology | 2 | 1.0 |
Osmolar Concentration | 5 | 0.0 |
Prospective Studies | 5 | 0.0 |
Radiotherapy, Adjuvant | 2 | 2.0 |
Hydrocortisone/*blood | 2 | 1.0 |
Aging/*metabolism | 3 | 1.0 |
Colon/metabolism | 2 | 1.0 |
Digestive System/*metabolism | 3 | 7.0 |
Duodenum/metabolism | 2 | 5.0 |
Galanin/metabolism | 3 | 37.0 |
Gastrins/metabolism | 4 | 21.0 |
Neurosecretory Systems/physiology | 2 | 14.0 |
Pyloric Antrum/metabolism | 2 | 33.0 |
Somatostatin/metabolism | 8 | 16.0 |
Duodenum/*metabolism | 2 | 10.0 |
Motilin/metabolism | 2 | 66.0 |
Cyclic AMP/analogs & derivatives/pharmacology | 2 | 25.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Acetylcholine/analysis | 2 | 66.0 |
Galanin/analysis | 7 | 70.0 |
Muscle, Smooth/chemistry/innervation | 3 | 60.0 |
Neurotransmitters/*analysis | 6 | 35.0 |
Norepinephrine/analysis | 3 | 17.0 |
Acetylcholinesterase/*metabolism | 2 | 1.0 |
Dogs | 15 | 1.0 |
Mesocricetus | 2 | 1.0 |
Tyrosine 3-Monooxygenase/*metabolism | 4 | 4.0 |
Bombesin/analysis | 9 | 50.0 |
Enkephalins/analysis | 9 | 81.0 |
Serotonin/*analysis | 3 | 30.0 |
NADPH Dehydrogenase/analysis | 7 | 46.0 |
Staining and Labeling | 3 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Cell Communication/*physiology | 2 | 3.0 |
Neuropeptides/physiology | 7 | 25.0 |
Neurotransmitters/*physiology | 8 | 25.0 |
Nitric Oxide/physiology | 2 | 4.0 |
Culture Media | 2 | 0.0 |
Endothelium, Vascular/*physiology | 4 | 2.0 |
Peptide PHI/pharmacology | 4 | 100.0 |
*Tachykinins | 2 | 100.0 |
Vasoactive Intestinal Peptide/analysis/pharmacology | 2 | 100.0 |
Acetylcholine/pharmacology | 6 | 8.0 |
Atropine/pharmacology | 5 | 12.0 |
Perfusion | 7 | 3.0 |
Serotonin/*metabolism | 2 | 4.0 |
Tetrodotoxin/pharmacology | 4 | 11.0 |
Vasoactive Intestinal Peptide/*pharmacology/physiology | 4 | 100.0 |
Iodine Radioisotopes/*diagnostic use | 2 | 3.0 |
Psoriasis/*metabolism | 3 | 12.0 |
Skin/*innervation | 7 | 33.0 |
Administration, Oral | 4 | 0.0 |
Fluorescent Antibody Technique, Direct | 2 | 1.0 |
Mucous Membrane/metabolism | 2 | 6.0 |
Blood Flow Velocity | 2 | 2.0 |
*Exercise | 2 | 1.0 |
*Exertion | 4 | 2.0 |
*Muscle Contraction | 2 | 6.0 |
*Vasodilation | 3 | 21.0 |
Dopamine beta-Hydroxylase/analysis | 11 | 50.0 |
Nerve Fibers/pathology | 4 | 16.0 |
*Embryonic and Fetal Development | 4 | 3.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Dopamine/*pharmacology | 2 | 7.0 |
Piperidines/*pharmacology | 2 | 3.0 |
Prolactin/*secretion | 6 | 3.0 |
Protirelin/pharmacology | 5 | 4.0 |
Neuroblastoma/*metabolism | 7 | 11.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Peptide PHI/*pharmacology | 3 | 100.0 |
Amidohydrolases/metabolism | 2 | 10.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Detergents | 3 | 2.0 |
Hydrogen-Ion Concentration | 8 | 0.0 |
Lipids/analysis | 2 | 4.0 |
Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 2 | 6.0 |
Solubility | 2 | 0.0 |
Vasoactive Intestinal Peptide/*diagnostic use | 3 | 100.0 |
Mice, Inbred NOD | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Transplantation, Autologous | 2 | 0.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Survival Rate | 3 | 0.0 |
Blood Pressure/drug effects | 10 | 1.0 |
Heart Rate/drug effects | 5 | 2.0 |
Infusions, Intravenous | 10 | 1.0 |
*Skin Physiology | 2 | 5.0 |
Gastrins/*blood | 7 | 16.0 |
Neurotensin/*blood | 3 | 60.0 |
Lymphocytes/immunology | 2 | 0.0 |
Neuroimmunomodulation/*immunology | 2 | 25.0 |
COS Cells | 3 | 0.0 |
GTP-Binding Proteins/metabolism | 5 | 1.0 |
Microscopy, Confocal | 6 | 0.0 |
Arteries | 2 | 3.0 |
Cyclooxygenase Inhibitors/pharmacology | 2 | 2.0 |
Indomethacin/pharmacology | 5 | 2.0 |
Uterus/*blood supply | 4 | 16.0 |
Vasodilation/*physiology | 3 | 16.0 |
Saliva/metabolism | 2 | 6.0 |
Vasoactive Intestinal Peptide/*secretion | 11 | 91.0 |
Capsaicin/pharmacology | 5 | 14.0 |
Peptides/*physiology | 5 | 11.0 |
Vasoactive Intestinal Peptide/immunology/*physiology | 2 | 100.0 |
*Allergens | 2 | 12.0 |
Molecular Weight | 10 | 0.0 |
Bronchi/*innervation | 4 | 100.0 |
Gastric Acid/*secretion | 3 | 4.0 |
Regional Blood Flow/drug effects | 10 | 9.0 |
Vasoactive Intestinal Peptide/pharmacology/*physiology | 3 | 100.0 |
Carbachol/pharmacology | 3 | 3.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Inositol 1,4,5-Trisphosphate/biosynthesis | 2 | 9.0 |
Parasympathetic Nervous System/*physiology | 2 | 14.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Autocrine Communication | 2 | 2.0 |
Bronchi/innervation | 3 | 100.0 |
Choline O-Acetyltransferase/metabolism | 5 | 3.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Pressure | 4 | 3.0 |
Neuropeptides/metabolism/*physiology | 2 | 22.0 |
Face | 2 | 8.0 |
Nerve Tissue Proteins/*analysis | 7 | 8.0 |
Adenosine Triphosphate/pharmacology | 2 | 2.0 |
Bucladesine/pharmacology | 7 | 3.0 |
Isoproterenol/pharmacology | 6 | 5.0 |
Dinoprostone/biosynthesis | 2 | 3.0 |
Oxygen/blood | 2 | 1.0 |
Pulmonary Circulation/drug effects | 2 | 18.0 |
Vascular Resistance/drug effects | 2 | 3.0 |
Vasodilation/*drug effects | 4 | 10.0 |
Neurotensin/physiology | 3 | 100.0 |
Somatostatin/physiology | 4 | 19.0 |
Substance P/physiology | 8 | 57.0 |
Nitric-Oxide Synthase/*analysis | 4 | 26.0 |
Seminal Vesicles/*innervation | 2 | 100.0 |
Enkephalin, Leucine/analysis | 3 | 60.0 |
Neurokinin A/analysis | 5 | 100.0 |
Intestinal Mucosa/metabolism | 9 | 8.0 |
Substance P/*metabolism | 11 | 37.0 |
Antibody Specificity | 6 | 0.0 |
Muscle Contraction/drug effects | 9 | 9.0 |
Salivary Glands/*innervation | 2 | 100.0 |
Calcitonin Gene-Related Peptide/*pharmacology | 4 | 30.0 |
Ciliary Neurotrophic Factor | 2 | 1.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Gallbladder/*innervation | 4 | 80.0 |
Neurons/*metabolism | 7 | 2.0 |
Phosphopyruvate Hydratase/metabolism | 3 | 5.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Gastrin-Releasing Peptide | 15 | 17.0 |
Peptides/analysis | 8 | 10.0 |
Acute Disease | 5 | 0.0 |
Neurotensin/metabolism | 4 | 40.0 |
Vasoactive Intestinal Peptide | 2 | 100.0 |
Zona Glomerulosa/drug effects/*metabolism | 2 | 66.0 |
Peptides/metabolism | 10 | 4.0 |
Glycopeptides/pharmacology | 3 | 25.0 |
Neurotransmitters/pharmacology | 3 | 33.0 |
Receptors, Pituitary Hormone/*genetics/metabolism | 2 | 100.0 |
Receptors, Vasoactive Intestinal Peptide/*genetics/metabolism | 2 | 100.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
Recombinant Proteins | 3 | 0.0 |
Bladder/*innervation | 3 | 60.0 |
Tyrosine 3-Monooxygenase/*analysis | 7 | 20.0 |
Diagnosis, Differential | 8 | 0.0 |
Diagnostic Imaging | 2 | 6.0 |
Osteoblasts/metabolism | 2 | 3.0 |
beta-Galactosidase/*genetics | 2 | 18.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Age Factors | 8 | 0.0 |
Interleukin-1/*biosynthesis | 2 | 1.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Neuropeptide Y/*pharmacology | 4 | 6.0 |
Peptides/*pharmacology | 6 | 2.0 |
Somatostatin/*pharmacology | 8 | 16.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
Receptors, Vasoactive Intestinal Peptide/*genetics | 2 | 25.0 |
Adipose Tissue/metabolism | 2 | 1.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Patch Tests | 2 | 6.0 |
Skin/*metabolism | 3 | 2.0 |
Histocytochemistry | 29 | 4.0 |
Adenylate Cyclase/*metabolism | 24 | 42.0 |
Brain Neoplasms/*pathology | 2 | 2.0 |
DNA Replication/drug effects | 2 | 1.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Gastrointestinal Hormones/blood | 2 | 40.0 |
Peptide YY | 8 | 6.0 |
Peptides/blood | 3 | 8.0 |
Substance P/blood | 8 | 80.0 |
Growth Hormone/blood | 4 | 1.0 |
Hydrocortisone/blood | 2 | 0.0 |
Injections, Intravenous | 5 | 0.0 |
Prolactin/blood | 6 | 1.0 |
Cell Count | 8 | 0.0 |
Rabbits | 20 | 0.0 |
Endothelin-1/analysis | 2 | 66.0 |
Secretory Rate/drug effects | 3 | 3.0 |
Escherichia coli/genetics | 2 | 0.0 |
Mast Cells/*pathology | 2 | 18.0 |
*Proctocolectomy, Restorative | 2 | 33.0 |
Postoperative Complications/*metabolism | 2 | 50.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Tissue Fixation | 3 | 3.0 |
NADPH Dehydrogenase/*analysis | 3 | 75.0 |
Ureter/*innervation | 3 | 60.0 |
Neuropeptides/*metabolism/pharmacology | 2 | 28.0 |
Prostate/*metabolism | 2 | 2.0 |
Vasoactive Intestinal Peptide/*metabolism/pharmacology | 9 | 100.0 |
Respiratory System/*innervation | 2 | 50.0 |
Succinimides/pharmacology | 2 | 16.0 |
Colon/*metabolism | 3 | 5.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 7 | 0.0 |
Acetylcholinesterase/analysis/metabolism | 2 | 33.0 |
Choline O-Acetyltransferase/analysis/metabolism | 2 | 33.0 |
DNA | 2 | 0.0 |
Colectomy | 3 | 10.0 |
Sex Characteristics | 2 | 0.0 |
Neoplasm Metastasis | 4 | 0.0 |
Colonic Neoplasms/pathology | 2 | 3.0 |
S100 Proteins/analysis | 4 | 2.0 |
Hypothalamus/metabolism | 2 | 4.0 |
Forearm/*blood supply | 2 | 9.0 |
Microcirculation/*drug effects | 2 | 50.0 |
Predictive Value of Tests | 2 | 0.0 |
Vasoconstriction/*drug effects | 2 | 5.0 |
Muscle, Smooth/physiology | 4 | 25.0 |
*Transcutaneous Electric Nerve Stimulation | 5 | 55.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
*Gene Expression Regulation | 4 | 0.0 |
Neuropeptides/immunology/*metabolism | 2 | 100.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Cats | 21 | 6.0 |
Muscle, Smooth/*drug effects/metabolism | 2 | 33.0 |
Brain Chemistry | 4 | 1.0 |
Microscopy, Immunoelectron | 5 | 0.0 |
Antibodies/immunology | 3 | 0.0 |
Neuropeptides/analysis/*metabolism | 2 | 50.0 |
Vasoactive Intestinal Peptide/analysis/metabolism | 2 | 100.0 |
Calcium/metabolism | 3 | 0.0 |
Drug Interactions | 6 | 0.0 |
Thrombin/pharmacology | 2 | 0.0 |
Adenocarcinoma | 3 | 2.0 |
Colonic Neoplasms | 3 | 2.0 |
Receptors, Gastrointestinal Hormone/*metabolism | 20 | 76.0 |
*Signal Transduction | 2 | 0.0 |
Neurons/enzymology | 5 | 11.0 |
Norepinephrine/pharmacology | 6 | 7.0 |
Vasoconstrictor Agents/pharmacology | 2 | 5.0 |
Chlorides/metabolism | 2 | 2.0 |
Skin/chemistry/*innervation | 2 | 100.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Ionophores/pharmacology | 2 | 1.0 |
NG-Nitroarginine Methyl Ester | 2 | 18.0 |
Peptides, Cyclic/*pharmacology | 2 | 9.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Neuroblastoma/metabolism | 3 | 5.0 |
Vasoactive Intestinal Peptide/blood/*physiology | 2 | 100.0 |
Alzheimer Disease/*metabolism/pathology | 2 | 2.0 |
Sex Factors | 5 | 0.0 |
Axons/metabolism/ultrastructure | 2 | 14.0 |
Neuropeptide Y/*analysis | 12 | 27.0 |
Muscle, Smooth/metabolism | 3 | 5.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Diabetic Neuropathies/*physiopathology | 2 | 14.0 |
Sweating/*drug effects | 2 | 100.0 |
Gastrins/analysis | 3 | 23.0 |
Arteries/drug effects | 4 | 33.0 |
Muscle, Smooth, Vascular/*drug effects | 3 | 15.0 |
Penis/blood supply/*drug effects | 2 | 100.0 |
Cystic Fibrosis/metabolism | 2 | 6.0 |
Receptors, Vasoactive Intestinal Peptide/*analysis/metabolism | 2 | 100.0 |
Vasomotor System/*drug effects | 2 | 28.0 |
Vasoactive Intestinal Peptide/*analysis/metabolism | 2 | 100.0 |
Peptides/*analysis | 8 | 11.0 |
Neurokinin A/pharmacology | 4 | 50.0 |
Bladder/chemistry/*innervation | 2 | 100.0 |
Amino Acid Oxidoreductases/*analysis | 3 | 75.0 |
Nitric-Oxide Synthase | 3 | 8.0 |
Penis/*chemistry/innervation | 2 | 100.0 |
Pancreatectomy | 2 | 8.0 |
Calcium/pharmacology | 3 | 1.0 |
Laser-Doppler Flowmetry | 3 | 7.0 |
Muscle Contraction | 2 | 3.0 |
Peptide PHI/analysis | 8 | 88.0 |
Rabbits/immunology | 2 | 2.0 |
Ischemic Attack, Transient/cerebrospinal fluid | 2 | 100.0 |
Jugular Veins | 2 | 14.0 |
Vasoactive Intestinal Peptide/*cerebrospinal fluid | 4 | 100.0 |
Lymphocytes/*metabolism | 3 | 1.0 |
Interferon Type II/*antagonists & inhibitors | 2 | 28.0 |
Hirschsprung Disease/*physiopathology | 3 | 75.0 |
Neurons/*enzymology | 2 | 2.0 |
Galanin | 9 | 23.0 |
Peptide Fragments/analysis | 4 | 1.0 |
Vascular Resistance/physiology | 2 | 9.0 |
Regression Analysis | 4 | 0.0 |
Pulmonary Circulation/*physiology | 2 | 15.0 |
Brain/*physiology | 2 | 1.0 |
Vasomotor System/*physiology | 3 | 33.0 |
Chromogranins/*analysis | 2 | 5.0 |
Hirschsprung Disease/*pathology | 3 | 30.0 |
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 1.0 |
Glycosylation | 2 | 0.0 |
Muscle, Smooth/drug effects/physiology | 2 | 22.0 |
Gastrointestinal Hormones/*blood | 32 | 32.0 |
Somatostatin/blood | 8 | 32.0 |
Chimera | 2 | 1.0 |
Glucose/pharmacology | 2 | 1.0 |
Glucose Tolerance Test | 4 | 0.0 |
Lymphocyte Activation/drug effects | 3 | 0.0 |
Progesterone/biosynthesis | 2 | 4.0 |
Tumor Cells, Cultured/drug effects/metabolism | 3 | 1.0 |
Norepinephrine/*analysis | 2 | 50.0 |
Vasoactive Intestinal Peptide/metabolism/*physiology | 3 | 100.0 |
Granulosa Cells/drug effects/metabolism | 2 | 18.0 |
Vasoactive Intestinal Peptide/*analysis/pharmacology | 3 | 100.0 |
Intestinal Mucosa/*metabolism | 2 | 2.0 |
Calcium/diagnostic use | 2 | 33.0 |
Chromatography | 2 | 1.0 |
Gastrointestinal Hormones/*secretion | 9 | 23.0 |
Secretin/diagnostic use | 2 | 33.0 |
Chemiluminescent Measurements | 3 | 1.0 |
Psoriasis/etiology/*metabolism/pathology | 2 | 100.0 |
Neurons/chemistry | 2 | 8.0 |
Protein Precursors/metabolism | 2 | 1.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Chromatography, Affinity | 4 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
Interleukin-6/*metabolism | 2 | 1.0 |
MSH/analysis | 3 | 42.0 |
Cluster Headache/metabolism/*physiopathology | 2 | 100.0 |
Guanosine Triphosphate/pharmacology | 3 | 11.0 |
Neurotensin/*secretion | 2 | 100.0 |
Pancreatic Polypeptide/secretion | 2 | 25.0 |
Vipoma/*diagnosis/secretion | 4 | 100.0 |
Diabetes Mellitus, Experimental/*surgery | 2 | 66.0 |
Insulin/analysis | 2 | 9.0 |
Arteries/innervation | 3 | 60.0 |
Autonomic Nervous System/*pathology | 2 | 100.0 |
Substance P/blood/secretion | 2 | 100.0 |
Xenon Radioisotopes/diagnostic use | 2 | 25.0 |
Esophagus/*physiology | 2 | 40.0 |
Exercise/*physiology | 2 | 0.0 |
Exercise Test | 3 | 1.0 |
Lymphocytes/*drug effects/metabolism | 2 | 6.0 |
Diarrhea/*drug therapy/etiology | 3 | 42.0 |
Octreotide/*therapeutic use | 2 | 5.0 |
Vasoactive Intestinal Peptide/blood/*secretion | 7 | 100.0 |
Aging/*physiology | 2 | 0.0 |
Receptors, Neurotransmitter/*physiology | 2 | 25.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Diabetic Neuropathies/*metabolism | 2 | 40.0 |
Gastrins/blood | 11 | 14.0 |
Pancreatic Polypeptide/blood | 12 | 20.0 |
Neuroblastoma/*pathology | 2 | 3.0 |
Vasoactive Intestinal Peptide/*antagonists & inhibitors | 3 | 100.0 |
Vasoactive Intestinal Peptide/immunology/metabolism | 2 | 100.0 |
Bicarbonates/metabolism | 4 | 21.0 |
Duodenum/*drug effects | 2 | 40.0 |
Pancreas/drug effects/*secretion | 2 | 28.0 |
Somatostatin/*blood | 3 | 16.0 |
Immunosorbent Techniques | 2 | 0.0 |
Central Nervous System/metabolism | 2 | 5.0 |
Vasoactive Intestinal Peptide/chemistry/*metabolism | 2 | 100.0 |
Circadian Rhythm/*physiology | 3 | 3.0 |
Heart Transplantation/*physiology | 2 | 9.0 |
Peptides/pharmacology | 8 | 4.0 |
Gastrointestinal Hormones/pharmacology | 3 | 33.0 |
Neurons, Afferent/metabolism | 2 | 16.0 |
Catalysis | 3 | 0.0 |
Vasoactive Intestinal Peptide/*blood/physiology | 3 | 100.0 |
Acetylcholine/*metabolism | 2 | 6.0 |
Atropine/*pharmacology | 3 | 16.0 |
Lung/innervation | 3 | 60.0 |
Muscle Contraction/*drug effects | 3 | 13.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 4 | 4.0 |
Peptic Ulcer/surgery | 2 | 66.0 |
Prolactin/*blood | 3 | 0.0 |
Neoplasms/*physiopathology | 3 | 11.0 |
Neuropeptides/*cerebrospinal fluid | 2 | 28.0 |
Neurotransmitters/*metabolism | 3 | 10.0 |
Immunoglobulin E/*biosynthesis | 2 | 4.0 |
Immunoglobulin G/*biosynthesis | 2 | 5.0 |
Monocytes/physiology | 2 | 1.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
*Brain Chemistry | 7 | 4.0 |
Nasal Mucosa/*innervation | 3 | 60.0 |
Histamine/pharmacology | 4 | 7.0 |
Membranes/enzymology | 2 | 22.0 |
Receptors, Cell Surface/drug effects/*metabolism | 2 | 4.0 |
Receptors, Gastrointestinal Hormone/metabolism | 6 | 60.0 |
*Receptors, Pituitary Hormone | 4 | 100.0 |
Vasoactive Intestinal Peptide/chemistry/metabolism | 2 | 100.0 |
Airway Resistance | 2 | 10.0 |
Thiolester Hydrolases/*metabolism | 2 | 25.0 |
Carbohydrates/metabolism | 2 | 3.0 |
Guanylyl Imidodiphosphate/pharmacology | 3 | 18.0 |
Vasoactive Intestinal Peptide/*blood/secretion | 4 | 100.0 |
Glucagon/blood | 7 | 7.0 |
Manometry | 4 | 11.0 |
Motilin/blood | 8 | 44.0 |
Peristalsis | 2 | 28.0 |
Epithelium | 3 | 5.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Neuroblastoma/*enzymology | 2 | 50.0 |
SRS-A/pharmacology | 2 | 28.0 |
Nerve Tissue Proteins/*pharmacology | 4 | 4.0 |
Potassium/blood | 3 | 3.0 |
Gene Expression/*physiology | 2 | 2.0 |
Receptors, Sensory/*physiology | 2 | 25.0 |
Regional Blood Flow | 3 | 2.0 |
Dermatitis, Atopic/*immunology | 2 | 4.0 |
Skin Tests | 2 | 1.0 |
Cell Adhesion | 2 | 0.0 |
Mast Cells/pathology | 2 | 5.0 |
Arthritis, Rheumatoid/*metabolism | 2 | 3.0 |
Nasal Mucosa/*secretion | 3 | 50.0 |
Autonomic Nervous System/*physiology | 4 | 30.0 |
Pylorus/*innervation | 2 | 100.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Vasoactive Intestinal Peptide/*immunology | 5 | 83.0 |
Sheep | 4 | 0.0 |
Forearm/blood supply | 2 | 4.0 |
Blood Glucose/metabolism | 8 | 1.0 |
Glucose/administration & dosage | 2 | 6.0 |
Dermatitis, Atopic/*metabolism/pathology | 2 | 40.0 |
Neuropeptides/*chemistry | 2 | 28.0 |
Hypotension/etiology | 2 | 18.0 |
Peptides/*blood | 5 | 7.0 |
Renin/blood | 4 | 1.0 |
Ureter/*innervation/physiology | 2 | 100.0 |
*Peptide Biosynthesis | 2 | 6.0 |
Neurons/physiology | 2 | 1.0 |
Binding Sites, Antibody | 3 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Superoxides/*metabolism | 2 | 2.0 |
Chromatography, Gel | 9 | 1.0 |
Vasoactive Intestinal Peptide/*analysis/physiology | 3 | 100.0 |
Colonic Neoplasms/*metabolism | 5 | 6.0 |
Microcirculation/drug effects | 2 | 7.0 |
Gastrointestinal Hormones/*metabolism | 14 | 58.0 |
Rats, Inbred Strains | 24 | 3.0 |
Lymphocytes/*drug effects | 2 | 4.0 |
Receptors, Neuropeptide Y | 2 | 6.0 |
Peptide Fragments/*analysis | 2 | 4.0 |
Skin/metabolism | 2 | 1.0 |
Cytoplasmic Granules/ultrastructure | 2 | 5.0 |
Protein Precursors/genetics | 3 | 3.0 |
Capsaicin/*pharmacology | 2 | 18.0 |
Histamine/*pharmacology | 3 | 8.0 |
Platelet Activating Factor/*pharmacology | 2 | 8.0 |
Catecholamines/metabolism | 2 | 4.0 |
Urethra/*physiology | 2 | 100.0 |
Cholecystokinin/metabolism | 2 | 13.0 |
Cross-Linking Reagents | 2 | 0.0 |
Hydrolysis | 3 | 0.0 |
Esophagogastric Junction/*physiopathology | 2 | 100.0 |
Growth Hormone/*blood | 2 | 1.0 |
Vasoactive Intestinal Peptide/administration & dosage/*pharmacology | 6 | 85.0 |
Alanine/chemistry | 2 | 2.0 |
Gastric Inhibitory Polypeptide/pharmacology | 2 | 40.0 |
Vasoactive Intestinal Peptide/immunology/*pharmacology | 3 | 75.0 |
Growth Hormone/secretion | 2 | 2.0 |
Vasoactive Intestinal Peptide/*analysis/blood | 7 | 100.0 |
Cell Membrane/enzymology | 5 | 2.0 |
Cerebral Arteries/*innervation | 2 | 100.0 |
Schizophrenia/*therapy | 2 | 50.0 |
*Schizophrenic Psychology | 2 | 3.0 |
*Treatment Outcome | 2 | 8.0 |
Vasoactive Intestinal Peptide/analysis/*physiology | 2 | 100.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Dementia/*cerebrospinal fluid | 2 | 18.0 |
Vasoactive Intestinal Peptide/cerebrospinal fluid | 2 | 100.0 |
Gastric Acid/secretion | 2 | 4.0 |
Acetylcholinesterase/metabolism | 2 | 2.0 |
Enkephalin, Methionine/metabolism | 3 | 42.0 |
Muscles/innervation | 3 | 18.0 |
Calcitonin/metabolism | 4 | 33.0 |
Histocytochemistry/methods | 2 | 11.0 |
Methacholine Chloride | 2 | 33.0 |
Methacholine Compounds/pharmacology | 2 | 33.0 |
Neurotensin/analysis | 6 | 60.0 |
Ileum/drug effects | 2 | 50.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Retina/*cytology | 2 | 18.0 |
Peptide PHI/*analysis | 3 | 100.0 |
Skin/innervation | 2 | 11.0 |
Colonic Neoplasms/*pathology | 2 | 2.0 |
Amino Acids/analysis | 3 | 1.0 |
Biological Assay | 2 | 0.0 |
Hirschsprung Disease/*metabolism | 3 | 60.0 |
Nerve Fibers/analysis | 2 | 28.0 |
Calcitonin/pharmacology | 2 | 9.0 |
Vasoactive Intestinal Peptide/blood/*metabolism | 3 | 100.0 |
Respiratory System/*metabolism | 2 | 14.0 |
Infant, Premature/*blood | 2 | 6.0 |
Cholera Toxin/pharmacology | 2 | 2.0 |
Cholecystokinin/blood | 5 | 9.0 |
Eating | 2 | 1.0 |
Neurotensin/blood | 2 | 28.0 |
Enteral Nutrition | 2 | 8.0 |
Neural Crest | 2 | 28.0 |
Muscle, Smooth/drug effects | 2 | 10.0 |
Penis/*innervation | 2 | 66.0 |
Vasoactive Intestinal Peptide/isolation & purification/*pharmacology | 2 | 100.0 |
Secretin/*pharmacology | 5 | 41.0 |
Mast Cells/physiology | 2 | 13.0 |
Blood Glucose/analysis | 9 | 1.0 |
Duodenum | 4 | 16.0 |
Enteroglucagon/blood | 3 | 42.0 |
Insulin/blood | 12 | 1.0 |
Skin/*drug effects | 4 | 26.0 |
Electric Conductivity | 2 | 1.0 |
Receptors, Gastrointestinal Hormone/*physiology | 2 | 40.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 3 | 3.0 |
Pituitary Hormones/analysis | 2 | 100.0 |
Hemodynamic Processes/*drug effects | 2 | 1.0 |
Immunoassay | 2 | 0.0 |
Immune Sera | 4 | 1.0 |
Protein Precursors/*analysis | 3 | 12.0 |
Intestine, Small/*embryology/metabolism | 2 | 66.0 |
*Neurotransmitters | 2 | 50.0 |
Substance P/*physiology | 3 | 50.0 |
Calcitonin Gene-Related Peptide | 15 | 60.0 |
Histamine Release/*drug effects | 3 | 10.0 |
Intestine, Small/*metabolism | 2 | 7.0 |
Receptors, Neurokinin-1 | 2 | 28.0 |
Digestive System/innervation | 2 | 100.0 |
Neurons/analysis | 3 | 37.0 |
Estradiol/blood | 2 | 0.0 |
Monocytes/*drug effects/metabolism | 2 | 2.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Receptors, Gastrointestinal Hormone/drug effects/*metabolism | 4 | 66.0 |
Tumor Cells, Cultured/drug effects/*metabolism | 2 | 8.0 |
Tumor Cells, Cultured/*metabolism | 2 | 6.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Secretin/physiology | 2 | 66.0 |
Intestinal Absorption | 4 | 2.0 |
*Food | 5 | 5.0 |
Obesity/*blood | 2 | 2.0 |
Adenylate Cyclase/analysis | 3 | 100.0 |
Celiac Disease/*metabolism | 2 | 50.0 |
Adenoma/enzymology/*metabolism | 2 | 50.0 |
Adenocarcinoma/*metabolism | 3 | 3.0 |
Glucagon/analysis | 3 | 16.0 |
Intestinal Mucosa/*analysis | 3 | 100.0 |
Pancreatic Polypeptide/analysis | 6 | 40.0 |
Secretin/analysis | 2 | 66.0 |
Neurons, Afferent/*analysis | 2 | 100.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Liver Diseases/*physiopathology | 2 | 33.0 |
3',5'-Cyclic-Nucleotide Phosphodiesterase/metabolism | 2 | 33.0 |
Adenoma, Islet Cell/*diagnosis | 3 | 100.0 |
Adenoma, Islet Cell/*secretion | 2 | 66.0 |
Neurons/*analysis | 3 | 27.0 |
Body Weight/drug effects | 2 | 1.0 |
Gastric Inhibitory Polypeptide/blood | 5 | 13.0 |
Secretin/blood | 5 | 50.0 |
Pancreas/*metabolism | 3 | 8.0 |
T-Lymphocytes/*cytology | 2 | 2.0 |
Digestive System/immunology | 2 | 40.0 |
Vasoactive Intestinal Peptide/analysis/*immunology | 2 | 100.0 |
*Electric Stimulation Therapy | 2 | 8.0 |
Skin Temperature | 5 | 14.0 |
Immunologic Techniques | 3 | 0.0 |
Penile Erection/*drug effects | 2 | 50.0 |
Octreotide | 2 | 16.0 |
Neuropeptides/analysis/*physiology | 3 | 100.0 |
Nerve Fibers/*analysis | 8 | 80.0 |
Respiratory System/*analysis | 2 | 100.0 |
Pancreatic Neoplasms/*diagnosis/secretion | 2 | 100.0 |
Intestines/*analysis | 3 | 37.0 |
Diarrhea/*etiology | 7 | 70.0 |
Vagus Nerve/physiology | 2 | 10.0 |
Naloxone/pharmacology | 2 | 4.0 |
Pancreatic Polypeptide/*blood | 4 | 20.0 |
Digestive System/analysis | 2 | 100.0 |
Pancreatic Neoplasms/*secretion | 5 | 50.0 |
Prolactin/blood/*secretion | 2 | 1.0 |
Injections, Intradermal | 2 | 4.0 |
Vasodilation | 2 | 5.0 |
Aldosterone/blood | 2 | 1.0 |
Acetylcholine/metabolism | 2 | 6.0 |
Dithiothreitol/pharmacology | 2 | 2.0 |
Synaptosomes/metabolism | 2 | 14.0 |
Propranolol/pharmacology | 2 | 4.0 |
Dietary Fats/administration & dosage | 2 | 2.0 |
Lung/*analysis | 2 | 28.0 |
Dinoprostone | 3 | 4.0 |
Prostaglandins E/pharmacology | 5 | 18.0 |
Adenocarcinoma/metabolism | 2 | 2.0 |
Immunochemistry | 5 | 2.0 |
Liver/metabolism | 2 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Colonic Neoplasms/metabolism | 2 | 3.0 |
Temperature | 5 | 0.0 |
Electrolytes/*metabolism | 2 | 28.0 |
Intestinal Absorption/*drug effects | 3 | 18.0 |
Vasoactive Intestinal Peptide/secretion | 3 | 100.0 |
Enkephalins/physiology | 2 | 40.0 |
Nerve Tissue Proteins/physiology | 2 | 4.0 |
Neuropeptide Y | 8 | 16.0 |
Peptide PHI | 17 | 100.0 |
Peptides/analysis/*physiology | 2 | 50.0 |
Enkephalins/*analysis | 3 | 50.0 |
Gastrins/*analysis | 2 | 50.0 |
Muscle, Smooth/analysis | 2 | 50.0 |
Goats | 2 | 2.0 |
Muscle, Smooth, Vascular/drug effects | 4 | 17.0 |
Sodium/metabolism | 4 | 2.0 |
Gastrointestinal Agents/*pharmacology | 2 | 22.0 |
*Lactation | 2 | 6.0 |
Enteroglucagon/metabolism | 3 | 100.0 |
Gastric Inhibitory Polypeptide/metabolism | 4 | 40.0 |
Protein Precursors/*genetics | 2 | 1.0 |
Glucagon/metabolism | 2 | 7.0 |
Secretin/metabolism | 2 | 40.0 |
Somatotropin-Releasing Hormone/metabolism | 3 | 37.0 |
Pituitary Gland, Anterior/drug effects/physiology | 2 | 66.0 |
*Receptors, Gastrointestinal Hormone | 2 | 66.0 |
Receptors, Cell Surface/*drug effects | 2 | 16.0 |
Endorphins/*pharmacology | 3 | 37.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
beta-Endorphin | 3 | 13.0 |
Nerve Tissue Proteins/*metabolism | 3 | 1.0 |
*Eating | 2 | 3.0 |
Peptides/chemistry | 2 | 0.0 |
Cross Reactions | 4 | 0.0 |
Cerebral Arteries/*metabolism | 2 | 40.0 |
Gastric Emptying | 2 | 14.0 |
Norepinephrine/*pharmacology | 2 | 10.0 |
Prostaglandins F/pharmacology | 2 | 14.0 |
Growth Hormone/analysis | 2 | 18.0 |
Nerve Tissue Proteins/*physiology | 3 | 4.0 |
Epithelium/metabolism | 2 | 0.0 |
Jejunum/*surgery | 2 | 20.0 |
Pancreatic Neoplasms/metabolism | 2 | 10.0 |
Receptors, Histamine/*drug effects | 2 | 100.0 |
Stomach Neoplasms/*analysis | 2 | 28.0 |
Digestive System/*analysis | 2 | 50.0 |
Gonadorelin/pharmacology | 2 | 4.0 |
Skin/*blood supply/innervation | 3 | 75.0 |
Amino Acids/pharmacology | 2 | 10.0 |
Pancreatic Polypeptide/physiology | 2 | 66.0 |
Calcitonin/blood | 2 | 6.0 |
Brain/enzymology | 2 | 1.0 |
Gastrointestinal Hormones/*analysis | 18 | 64.0 |
Radioimmunoassay/methods | 4 | 2.0 |
Spinal Cord/*analysis | 2 | 28.0 |
Vasoactive Intestinal Peptide/blood/*diagnostic use | 2 | 100.0 |
Gastrointestinal Hormones/*pharmacology | 12 | 42.0 |
Raynaud Disease/*blood | 2 | 28.0 |
*Fasting | 2 | 8.0 |
Infusions, Parenteral | 3 | 2.0 |
Secretin/*blood | 3 | 60.0 |
Diarrhea, Infantile/*etiology | 2 | 100.0 |
Fasting | 5 | 1.0 |
*Nutrition | 2 | 5.0 |
Acromegaly/*blood | 2 | 10.0 |
Growth Hormone/blood/*secretion | 2 | 2.0 |
Pituitary Hormones, Anterior/blood | 2 | 12.0 |
Pulse/drug effects | 3 | 15.0 |
Vasoactive Intestinal Peptide/blood/*pharmacology | 2 | 66.0 |
Diarrhea/*blood | 3 | 100.0 |
Peptides/*secretion | 2 | 15.0 |
Colon/innervation | 3 | 42.0 |
Haplorhini | 2 | 0.0 |
Food | 4 | 3.0 |
Sodium Chloride/pharmacology | 2 | 2.0 |
Cell Fractionation | 3 | 1.0 |
Gastrointestinal Hormones/*biosynthesis | 2 | 50.0 |
Apudoma/*secretion | 2 | 100.0 |
Ganglioneuroma/complications/*surgery | 2 | 100.0 |
Pruritus/*chemically induced | 2 | 25.0 |
Endorphins/*analysis | 2 | 40.0 |
Sodium Fluoride/pharmacology | 2 | 8.0 |
Jejunum/*metabolism | 3 | 25.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Central Nervous System/*physiology | 2 | 12.0 |
Gastric Juice/*secretion | 2 | 18.0 |
Gastric Inhibitory Polypeptide/*blood | 2 | 3.0 |
Gastrointestinal Hormones/*physiology | 3 | 20.0 |
Streptozocin/therapeutic use | 2 | 50.0 |
Severity of Illness Index | 3 | 0.0 |
Pancreatic Neoplasms/complications | 3 | 42.0 |
Radioimmunoassay/*methods | 2 | 2.0 |
Jejunum/metabolism | 2 | 14.0 |
Diarrhea/etiology | 2 | 11.0 |
Biopsy, Needle | 2 | 0.0 |
